Drugs / Glecaprevir-pibrentasvir
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03364725 | Jan → Sep 2018 | hepatitis C virus infection, heroin dependence | Id Care | Unknown | No outcome recorded |
| Phase 4 | NCT03208244 | Nov 2017 → Apr 2021 | hepatitis C virus infection | Massachusetts General Hospital | Terminated | Met primary Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | glecaprevir-pibrentasvir | “Patients who underwent transplantation with a viraemic donor heart, as determined by nucleic acid testing (NAT), received pre-emptive oral glecaprevir-pibrentasvir before...” PMID 31353243 ↗ Jul 2019 |
| Route | Oral | “received pre-emptive oral glecaprevir-pibrentasvir” PMID 31353243 ↗ Jul 2019 |